the researchers note that patients can get cheaper, generic versions of statins and ssris, and drug companies rely on marketing to increase the number of prescriptions written for the brand name versions. overall there were negligible to small effects of the disclosure laws in maine and west virginia for both statins and ssris, nairs group concluded.